ArticleJournal of clinical orthopaedics and trauma2025
Pathological Site Pain During Injections as a Predictive Sign for Clinical Response in Autologous Protein Solution and Hyaluronic Acid Injections for Knee Osteoarthritis.
Article in Journal of clinical orthopaedics and trauma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Autologous peripheral blood-derived orthobiologics like platelet-rich plasma (PRP) have been gaining in popularity in symptomatic relief of knee osteoarthritis (OA). Autologous protein solution (APS) that is derived from PRP offers higher levels of growth factors and anti-inflammatory cytokines, reducing inflammation and improve cartilage quality. Additionally, hyaluronic acid (HA) has shown efficacy in relieving OA symptoms. This study aims to assess the clinical outcomes of combined APS and HA therapy, particularly a presence of pathological site pain (PSP) during injection as a predictive sign for clinical response. Methods: Patients with early-stage OA received APS and HA injections. Patients were evaluated pre-injection and at 1-year follow-up. Patient-reported outcomes were assessed with WOMAC, KOOS, VAS pain score, and SF-36 survey. The OMERACT-OARSI criteria determined treatment effects. Satisfaction and expectation fulfillment were also recorded. Results: 32 patients were included in the final analysis. Statistically significant improvements were observed in all outcome scores at 1 year. The responder rate per OMERACT-OARSI criteria was 65.6 %, with 96.9 % of patients reporting satisfaction and expectation fulfillment. When comparing responder-rates and improvement in patient-reported outcome measures with other studies, combined therapy does not appear to confer additional therapeutic benefit over APS monotherapy at the 1-year mark. No severe adverse events related to the injections were reported. Patients with PSP had significantly better outcomes in terms of pain, stiffness, symptoms, activities of daily living, quality of life, as well as statistically significantly higher satisfaction rates of expectation fulfilment. Conclusions: At 1-year post-injection, the APS and HA combination significantly improved WOMAC, KOOS, SF-36 PCS, and VAS scores, with a high rate of patient satisfaction. PSP during injection could possibly be predictive of better outcomes and expectation fulfilment. Level of evidence: Level III.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.